GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Total Current Liabilities

Spark Therapeutics (Spark Therapeutics) Total Current Liabilities : $100.30 Mil (As of Sep. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Spark Therapeutics's total current liabilities for the quarter that ended in Sep. 2019 was $100.30

Spark Therapeutics Total Current Liabilities Historical Data

The historical data trend for Spark Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics Total Current Liabilities Chart

Spark Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Current Liabilities
Get a 7-Day Free Trial 15.85 22.12 30.00 53.69 62.35

Spark Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.32 62.35 86.44 90.40 100.30

Spark Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Spark Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=38.707+4.822
+Other Current Liabilities+Current Deferred Liabilities
=17.46+1.365
=62.35

Spark Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2019 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=45.084+16.197
+Other Current Liabilities+Current Deferred Liabilities
=16.898+22.12
=100.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Spark Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Spark Therapeutics (Spark Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Total Current Liabilities
Comparable Companies
TSE:4974 GBT IMMU RARE CRSP XSWX:GALE SZSE:002821 XBRU:ARGX AKCA XKRX:006280 SZSE:300294 EBS FOLD ANAB PBYI XON ASND HALO ROCO:4147 DNLI
Traded in Other Exchanges
N/A
Address
3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Website
http://www.sparktx.com
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.
Executives
Elliot Sigal director
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster officer: CHIEF FINANCIAL OFFICER C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga officer: Chief Business Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth director, officer: CHIEF SCIENTIFIC OFFICER 334 CR 692, BUFFALO GAP TX 79508
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High director, officer: See Remarks 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey officer: Chief Operating Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio officer: Chief Commercial Officer 225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Spark Therapeutics (Spark Therapeutics) Headlines

From GuruFocus

Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights

By Marketwired Marketwired • 07-31-2018

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

By Marketwired Marketwired • 10-08-2018

Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference

By Marketwired Marketwired • 01-02-2019

SPARK THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

By Marketwired Marketwired • 03-12-2019

Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™

By Marketwired Marketwired • 01-31-2019

Rigrodsky & Long, P.A. Files Class Action Suit Against Spark Therapeutics, Inc.

By Marketwired Marketwired • 04-05-2019

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

By Marketwired Marketwired • 10-25-2019

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spark Therapeutics, Inc. - ONCE

By PRNewswire PRNewswire • 03-12-2019

Spark: Down but Not Out!

By Maxwell Koobatian Maxwell Koobatian • 08-12-2018

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting

By Marketwired Marketwired • 10-30-2018